Identifikasi Drug Related Problems (DRPs) Penggunaan Antihipertensi Pada Pasien Geriatri di Instalasi Rawat Inap RSUP H. Adam Malik Medan

Abstract

Background: Drug-Related Problem (DRP) is an event or circumstance involving drug therapy that actually or potentially interferes with desired health outcomes. High of using drug combination and pharmacokinetics and pharmacodynamics changes of age-related cause the geriatrics of hypertension patients who susceptible to drug related problems (DPSs). Objective: This study was to determine the occurrence of DRPs in the use of antihypertension on geriatric inpatients at H. Adam Malik Hospital Medan period January-December 2022. Method: This study was a descriptive retrospective cross-sectional study conducted at H. Adam Malik Hospital Medan with medical record data containing antihypertension period January-December 2022. The occurrence of DRPs was analyzed based on Pharmaceutical Care Network Europe (PCNE) classification V9.1. Results: From the 132 medical records analyzed, it was found that the highest number of patients were women (59.09%), the largest age group was 60-65 years old (41.66%), the longest length of stay was 6-10 days (52.27%), the most dosage form was tablets (98.48%), the most given antihypertension were calcium channel blockers (CCB) (37,9%), the most dosage form was combination (31,61%), the most diagnoses are COVID-19 and essential hypertension (11.35%). Of the 132 patients there were 18 patients (13,63%) who experienced DRPs. Identification of DRPs in the problems (P) category was 18 events, namely treatment effectiveness (27,77%) and treatment safety (72,22%). While in the category of causes (C) DRPs, there were 18 events, namely in terms of drug selection (77,77%) and dose selection (22,22%). Conclusion: There were DRPs on the use of antihypertension on geriatric inpatients at H. Adam Malik Hospital Medan period January-December 2022. As many as 18 patients in the problems (P) category as many as 18 events, namely treatment effectiveness as many as 5 events (27,77%) and treatment safety as many as 13 events (72,22%). There were 18 causes (C) of DRPs found, namely in terms of drug selection as many as 14 events (77,77%) and dose selection as many as 4 events (22,22%)